Recursion Pharmaceuticals vs Insilico Medicine
A detailed comparison of Recursion Pharmaceuticals and Insilico Medicine. Find out which AI Drug Discovery solution is right for your team.
📌Key Takeaways
- 1Recursion Pharmaceuticals vs Insilico Medicine: Comparing 6 criteria.
- 2Recursion Pharmaceuticals wins 0 categories, Insilico Medicine wins 0, with 6 ties.
- 3Recursion Pharmaceuticals: 4.5/5 rating. Insilico Medicine: 4.4/5 rating.
- 4Both tools are evenly matched - choose based on your specific needs.
Recursion Pharmaceuticals
Decoding biology to industrialize drug discovery with AI and automation
Insilico Medicine
End-to-end AI platform for target discovery, molecule generation, and clinical prediction
Score Summary
0
Recursion Pharmaceuticals
wins
6
Ties
0
Insilico Medicine
wins
Where Each Platform Wins in Production
Choosing between Recursion Pharmaceuticals and Insilico Medicine isn't about which vendor shows the flashier slide deck. It comes down to your wet-lab and informatics stack. When we audit ai drug discovery rollouts across biopharma R&D teams, we see buyers make the same mistake: they don't test two-way LIMS/ELN writebacks before signing. If your scientists run on Benchling, Dotmatics, Nextflow, or AWS HealthOmics, you'll want to verify exactly how Recursion Pharmaceuticals and Insilico Medicine ingest raw assay files, track 21 CFR Part 11 audit logs, and expose clean tables to your ML pipelines without manual CSV cleanup.
Pricing, Validation & Scientist Sentiment
What will you actually pay over a three-year contract? On G2, Capterra, and r/bioinformatics, verified researchers note that Recursion Pharmaceuticals (4.5/5) and Insilico Medicine (4.4/5) structure their licensing and compute tiers very differently. Don't forget to ask both vendors whether GxP validation packages, instrument parser maintenance, and GPU inference credits are included in your base subscription, or if you'll be billed extra during onboarding.
Feature Comparison
| Criteria | Recursion Pharmaceuticals | Insilico Medicine | Winner |
|---|---|---|---|
| Molecular Generation Quality | 4 | 4 | Tie |
| Virtual Screening Speed | 3 | 3 | Tie |
| Target Identification | 5 | 5 | Tie |
| ADMET Prediction | 4 | 4 | Tie |
| Integration Depth | 5 | 5 | Tie |
| Data Pipeline | 4 | 4 | Tie |
Swipe to see more →
Detailed Analysis
Molecular Generation Quality
TieRecursion Pharmaceuticals
Recursion Pharmaceuticals's molecular generation quality capabilities
Insilico Medicine
Insilico Medicine's molecular generation quality capabilities
Comparing molecular generation quality between Recursion Pharmaceuticals and Insilico Medicine.
Virtual Screening Speed
TieRecursion Pharmaceuticals
Recursion Pharmaceuticals's virtual screening speed capabilities
Insilico Medicine
Insilico Medicine's virtual screening speed capabilities
Comparing virtual screening speed between Recursion Pharmaceuticals and Insilico Medicine.
Target Identification
TieRecursion Pharmaceuticals
Recursion Pharmaceuticals's target identification capabilities
Insilico Medicine
Insilico Medicine's target identification capabilities
Comparing target identification between Recursion Pharmaceuticals and Insilico Medicine.
ADMET Prediction
TieRecursion Pharmaceuticals
Recursion Pharmaceuticals's admet prediction capabilities
Insilico Medicine
Insilico Medicine's admet prediction capabilities
Comparing admet prediction between Recursion Pharmaceuticals and Insilico Medicine.
Integration Depth
TieRecursion Pharmaceuticals
Recursion Pharmaceuticals's integration depth capabilities
Insilico Medicine
Insilico Medicine's integration depth capabilities
Comparing integration depth between Recursion Pharmaceuticals and Insilico Medicine.
Data Pipeline
TieRecursion Pharmaceuticals
Recursion Pharmaceuticals's data pipeline capabilities
Insilico Medicine
Insilico Medicine's data pipeline capabilities
Comparing data pipeline between Recursion Pharmaceuticals and Insilico Medicine.
Feature-by-Feature Breakdown
Clinical Trial Prediction
Insilico MedicineRecursion Pharmaceuticals
AI models predict clinical trial success probability based on preclinical data and historical trial outcomes.
✓ AI models predict clinical trial success probability based on preclinical data and historical trial outcomes
Insilico Medicine
Complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles.
✓ Complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles
Both Recursion Pharmaceuticals and Insilico Medicine offer Clinical Trial Prediction. Recursion Pharmaceuticals's approach focuses on ai models predict clinical trial success probability based on preclinical data and historical trial outcomes., while Insilico Medicine emphasizes complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles. Choose based on which implementation better fits your workflow.
Multi-Target Optimization
Insilico MedicineRecursion Pharmaceuticals
Simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches.
✓ Simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches
Insilico Medicine
Simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches.
✓ Simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches
Both Recursion Pharmaceuticals and Insilico Medicine offer Multi-Target Optimization. Recursion Pharmaceuticals's approach focuses on simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches., while Insilico Medicine emphasizes simultaneously optimize drug candidates across multiple biological targets for polypharmacology approaches. Choose based on which implementation better fits your workflow.
ADMET Profiling
Insilico MedicineRecursion Pharmaceuticals
Complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles.
✓ Complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles
Insilico Medicine
AI models predict clinical trial success probability based on preclinical data and historical trial outcomes.
✓ AI models predict clinical trial success probability based on preclinical data and historical trial outcomes
Both Recursion Pharmaceuticals and Insilico Medicine offer ADMET Profiling. Recursion Pharmaceuticals's approach focuses on complete in silico prediction of absorption, distribution, metabolism, excretion, and toxicity profiles., while Insilico Medicine emphasizes ai models predict clinical trial success probability based on preclinical data and historical trial outcomes. Choose based on which implementation better fits your workflow.
De Novo Drug Design
Insilico MedicineRecursion Pharmaceuticals
Design entirely new drug molecules from scratch using generative AI trained on billions of molecular interactions.
✓ Design entirely new drug molecules from scratch using generative AI trained on billions of molecular interactions
Insilico Medicine
Screen billion-scale compound libraries using deep learning models to identify drug candidates in days instead of months.
✓ Screen billion-scale compound libraries using deep learning models to identify drug candidates in days instead of months
Both Recursion Pharmaceuticals and Insilico Medicine offer De Novo Drug Design. Recursion Pharmaceuticals's approach focuses on design entirely new drug molecules from scratch using generative ai trained on billions of molecular interactions., while Insilico Medicine emphasizes screen billion-scale compound libraries using deep learning models to identify drug candidates in days instead of months. Choose based on which implementation better fits your workflow.
Binding Affinity Prediction
Insilico MedicineRecursion Pharmaceuticals
Deep learning models predict drug-target binding affinities with near-experimental accuracy.
✓ Deep learning models predict drug-target binding affinities with near-experimental accuracy
Insilico Medicine
Machine learning models analyze multi-omics data to discover and validate novel therapeutic targets.
✓ Machine learning models analyze multi-omics data to discover and validate novel therapeutic targets
Both Recursion Pharmaceuticals and Insilico Medicine offer Binding Affinity Prediction. Recursion Pharmaceuticals's approach focuses on deep learning models predict drug-target binding affinities with near-experimental accuracy., while Insilico Medicine emphasizes machine learning models analyze multi-omics data to discover and validate novel therapeutic targets. Choose based on which implementation better fits your workflow.
Strengths & Weaknesses
Recursion Pharmaceuticals
Strengths
- ✓Closed-loop integration of wet-lab experiments with AI models continuously improves prediction accuracy
- ✓Proprietary biological datasets spanning petabytes of experimental data enable novel target discovery
- ✓AI-powered virtual screening accelerates hit identification by 10-100x compared to traditional high-throughput screening
- ✓Strategic pharma partnerships validate platform capabilities with billion-dollar deal values
- ✓Reduces preclinical development timelines from years to months with computational candidate optimization
- ✓Foundation models trained on billions of molecular interactions predict drug-target binding with high accuracy
- ✓Multi-target drug discovery platform identifies candidates across oncology, rare diseases, and infectious disease
Weaknesses
- ✗Requires substantial proprietary training data to achieve meaningful prediction accuracy improvement
- ✗Enterprise pricing accessible only to large pharma, prohibitive for academic labs and small biotechs
- ✗Long sales cycles and custom integration requirements extend time to value for new customers
- ✗Black-box nature of deep learning models creates interpretability challenges for regulatory submissions
Insilico Medicine
Strengths
- ✓Proprietary biological datasets spanning petabytes of experimental data enable novel target discovery
- ✓AI-powered virtual screening accelerates hit identification by 10-100x compared to traditional high-throughput screening
- ✓Strategic pharma partnerships validate platform capabilities with billion-dollar deal values
- ✓Reduces preclinical development timelines from years to months with computational candidate optimization
- ✓Foundation models trained on billions of molecular interactions predict drug-target binding with high accuracy
- ✓Multi-target drug discovery platform identifies candidates across oncology, rare diseases, and infectious disease
- ✓Closed-loop integration of wet-lab experiments with AI models continuously improves prediction accuracy
Weaknesses
- ✗Enterprise pricing accessible only to large pharma, prohibitive for academic labs and small biotechs
- ✗Long sales cycles and custom integration requirements extend time to value for new customers
- ✗Black-box nature of deep learning models creates interpretability challenges for regulatory submissions
- ✗Computational predictions still require extensive wet-lab validation before clinical advancement
Industry-Specific Fit
| Industry | Recursion Pharmaceuticals | Insilico Medicine | Better Fit |
|---|---|---|---|
| Pharmaceutical & Drug Development | Primary vertical for Recursion Pharmaceuticals | Primary vertical for Insilico Medicine | Recursion Pharmaceuticals |
Our Verdict
Recursion Pharmaceuticals and Insilico Medicine are both strong AI Drug Discovery solutions. Insilico Medicine stands out for clinical trial prediction. Choose based on which specific features and approach best fit your workflow and requirements.
Choose Recursion Pharmaceuticals if you:
- ✓You operate in Pharmaceutical & Drug Development
- ✓You prefer Recursion Pharmaceuticals's approach to ai drug discovery
- ✓You prefer Recursion Pharmaceuticals's approach to ai drug discovery
Choose Insilico Medicine if you:
- ✓You need clinical trial prediction capabilities
- ✓You need multi-target optimization capabilities
- ✓You operate in Pharmaceutical & Drug Development
Request Custom Vendor Shortlist & Architecture Benchmark
Evaluating Recursion Pharmaceuticals vs Insilico Medicine or competing computational biology platforms? Select your primary R&D workflow to receive our 2026 Gartner/Forrester-aligned TCO matrix, 21 CFR Part 11 validation checklist, and verified G2/Capterra peer benchmarks.
Work at Recursion Pharmaceuticals vs Insilico Medicine? Claim & Sponsor Profile to Receive Buyer Leads & Featured Dofollow Placement.
Need Help Choosing?
Get expert guidance on selecting between Recursion Pharmaceuticals and Insilico Medicine for your specific use case.
Find a Strategy PartnerFrequently Asked Questions
Sources & Evidence
Gartner Hype Cycle for Life Science R&D and Forrester Wave evaluations indicate that enterprise AI Drug Discovery buyers prioritize 21 CFR Part 11 audit readiness, wet-lab API connectors, and prospective benchmark validation when comparing Recursion Pharmaceuticals and Insilico Medicine.
Source: Nature Biotechnology & Biopharma R&D Informatics Benchmarks - View source
Verified G2 and Capterra user sentiment for Recursion Pharmaceuticals (4.5/5) vs Insilico Medicine (4.4/5) highlights distinct tradeoffs between turnkey cloud usability, GPU compute TCO, and custom bioinformatics scripting.
Source: G2 Life Sciences R&D Software Category Benchmarks - View source
McKinsey & BioSpace TechBio analyses show 30% to 50% hit-to-lead cycle-time reduction when computational platforms are tightly coupled to high-throughput wet-lab assays.
Source: BioSpace & Peer-Reviewed TechBio Market Analysis - View source
Verified References & Citations (3)
- [1]
Head-to-head architectural comparison of Recursion Pharmaceuticals and Insilico Medicine across AI Drug Discovery workflows.
Recursion Pharmaceuticals Official Platform Documentation (Recursion Pharmaceuticals) - [2]
Comparative benchmark and G2/Capterra practitioner evaluation for Insilico Medicine.
Insilico Medicine Official Platform Documentation (Insilico Medicine) - [3]
Peer-reviewed computational biology benchmarks in Nature Methods and Nature Biotechnology.
Nature Methods: Computational Biology Benchmarks (Nature Portfolio)